Sionna Therapeutics today announced the official launch of the company and the closing of a $111 million Series B financing. The round was led by OrbiMed with participation from funds advised by T.

The first CF rat model, CFTR tm1sage (termed CFTR-/- or KO), was designed in collaboration with SAGE (now Horizon Discovery) and subsequently characterized at UAB and distributed to the CF community.

UCLA researchers have developed a lipid nanoparticle-based gene-editing approach capable of inserting an entire healthy gene into human airway cells, restoring key biological function in a laboratory ...

CFTR is a protein essential to wet surfaces throughout your body, like the airways of your lungs. People with cystic fibrosis have a gene mutation that causes problems with the protein. Some ...

An experimental drug suggests that a 'path is clearly achievable' to treat currently untreatable cases of cystic fibrosis disease caused by nonsense mutations. This includes about 11 percent of cystic ...

North Chicago, Illinois — A research team at Rosalind Franklin University of Medicine and Science has developed a promising new therapeutic approach for the treatment of cystic fibrosis, a devastating ...

Adding either of two new drugs — VX-659 or VX-445 — to the standard tezacaftor-ivacaftor combination improves both lung function and sweat chloride concentrations in most patients with cystic fibrosis ...

The past couple of decades have seen huge advances in treatments and life expectancy for people with cystic fibrosis. But a fundamental question surrounding the genetic malady remains unanswered. To ...

Detailed price information for Sionna Therapeutics Inc (SION-Q) from The Globe and Mail including charting and trades.